Xenon Pharmaceuticals Inc. filings document a Nasdaq-listed Canadian biopharmaceutical issuer developing ion channel modulators for neurological and psychiatric disorders. Recent Form 8-K reports cover operating results, Regulation FD clinical disclosures, azetukalner study updates, investor presentation materials and exhibits tied to company press releases.
The filing record also includes proxy materials for shareholder voting and executive compensation, amendments to inducement equity incentive plans, registration and prospectus materials for common-share sales, pre-funded warrant and underwriting agreements, at-the-market offering disclosures, and capital-structure information for XENE common shares.
XENE filed a Form 144 to sell 20,000 common shares tied to a performance share unit award that vested on 03/09/2026.
The filing lists prior proposed or completed sales by Ian Mortimer of 40,000 shares on 01/02/2026 and 270,000 shares on 03/09/2026. The notice names Morgan Stanley Wealth Management Canada Inc. as the broker and shows the securities as Common Shares to be sold on NASDAQ.
Xenon Pharmaceuticals Inc. is offering $500.0 million of its common shares pursuant to a preliminary prospectus supplement. The underwriters have a 30-day option to purchase an additional $75.0 million of common shares. The company’s common shares trade on Nasdaq under the symbol XENE, with the last reported sale price of $41.94 on March 6, 2026. The prospectus supplement states 80,010,790 common shares outstanding as of December 31, 2025, and assumes no exercise of the underwriters’ option for outstanding-share calculations. The filing also discloses positive Phase 3 topline results for azetukalner in focal onset seizures and a planned NDA submission in Q3 2026 for that indication.
XENE files a Form 144 reporting the proposed sale of 270,000 common shares through the exercise of options on 03/09/2026. The filing also records a prior sale of 40,000 common shares by Ian Mortimer on 01/02/2026 and shows 1,777,166 shares associated with that holder.
Xenon Pharmaceuticals reported positive Phase 3 results from its X-TOLE2 study of azetukalner in adults with focal onset seizures. The trial met its primary endpoint, with median percent change in monthly seizure frequency of -53.2% for the 25 mg dose and -34.5% for 15 mg, versus -10.4% for placebo, giving a placebo-adjusted effect of -42.7% for 25 mg. Key secondary goals were also achieved, including responder rates (≥50% seizure reduction) of 54.8% for 25 mg and 37.6% for 15 mg, versus 20.8% for placebo. Safety and tolerability were generally consistent with prior studies, though dizziness and other nervous system side effects were more frequent at higher doses. Xenon plans to submit a New Drug Application to the FDA for focal onset seizures in the third quarter of 2026 and is preparing for potential commercialization.
Xenon Pharmaceuticals Inc. filed a prospectus supplement to register $400,000,000 of common shares for issuance under its at-the-market equity offering sales agreement with Jefferies and Stifel. This keeps the company’s ATM capacity available for future issuances under an existing sales framework.
The new prospectus supplement replaces and supersedes a prior prospectus, and the earlier offering has been terminated. As of the filing date, the company had already sold $291,084,564 in common shares under the sales agreement pursuant to the prior prospectus.
Xenon Pharmaceuticals Inc. is filing a prospectus supplement to offer up to $400,000,000 of common shares through an at-the-market equity program with Jefferies LLC and Stifel, Nicolaus & Company as sales agents.
The prospectus supplement replaces a prior prospectus and states that $291,084,564 of Shares have previously been sold under the Sales Agreement. The offering contemplates sales on the Nasdaq Global Market at prices that will vary; the supplement cites a last reported sale price of $44.92 per share on February 26, 2026. The disclosure notes estimated underwriting commissions up to 3.0%, customary indemnities to agents, intended uses of proceeds to fund clinical development and corporate purposes, and that there is no escrow arrangement. Shares outstanding were 80,010,790 as of December 31, 2025.
Xenon Pharmaceuticals filed its annual report describing a late-stage neuroscience pipeline led by azetukalner, a Kv7 potassium channel opener in multiple Phase 3 trials for focal onset and primary generalized tonic-clonic seizures, as well as major depressive disorder and bipolar depression.
The company highlights strong Phase 2b X-TOLE epilepsy data showing meaningful seizure reductions and generally manageable side effects, plus proof-of-concept antidepressant results from X-NOVA supporting the Phase 3 MDD and BPD programs. Early-stage Nav1.7, Nav1.1 and Kv7 pain programs and a sodium-channel collaboration with Neurocrine further expand its ion-channel portfolio.
Xenon Pharmaceuticals reported a larger net loss in 2025 as it ramped up late-stage clinical development of its lead epilepsy and mood-disorder drug azetukalner. Net loss was $345.9 million for 2025, compared with $234.3 million in 2024, driven mainly by higher research and development spending.
Research and development expenses rose to $300.9 million in 2025 from $210.4 million, reflecting multiple Phase 3 studies in epilepsy, major depressive disorder and bipolar depression, as well as early-stage pipeline work. General and administrative expenses increased to $79.6 million from $68.9 million.
Cash, cash equivalents and marketable securities were $586.0 million as of December 31, 2025, and pro forma cash including first-quarter 2026 at-the-market share sales was $716.0 million. The company raised $242.2 million through its at-the-market facility and expects its cash to fund operations into the second half of 2027, while key Phase 3 azetukalner data readouts begin in March 2026.
Wellington Management has disclosed a sizeable institutional stake in Xenon Pharmaceuticals Inc. (XENE). As of December 31, 2025, Wellington entities report beneficial ownership of 4,764,779 shares of Xenon common stock, representing about 6.17% of the outstanding shares.
Across the listed Wellington entities, there is no sole voting or dispositive power; voting and investment decisions are reported as shared over most of these shares. The filing explains that the securities are owned of record by Wellington investment-adviser clients, who receive dividends and sale proceeds, while no single client holds more than five percent of the class. Wellington certifies the position is held in the ordinary course of business and not for the purpose of influencing control of Xenon.